Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

β-Carboline derivatives as novel antivirals for herpes simplex virus.

Gonzalez MM, Cabrerizo FM, Baiker A, Erra-Balsells R, Osterman A, Nitschko H, Vizoso-Pinto MG.

Int J Antimicrob Agents. 2018 Oct;52(4):459-468. doi: 10.1016/j.ijantimicag.2018.06.019. Epub 2018 Jul 10.

PMID:
30006037
2.

The Hepatitis E virus intraviral interactome.

Osterman A, Stellberger T, Gebhardt A, Kurz M, Friedel CC, Uetz P, Nitschko H, Baiker A, Vizoso-Pinto MG.

Sci Rep. 2015 Oct 14;5:13872. doi: 10.1038/srep13872.

3.

BK virus infection activates the TNFα/TNF receptor system in Polyomavirus-associated nephropathy.

Ribeiro A, Merkle M, Motamedi N, Nitschko H, Köppel S, Wörnle M.

Mol Cell Biochem. 2016 Jan;411(1-2):191-9. doi: 10.1007/s11010-015-2581-1. Epub 2015 Oct 7.

PMID:
26446017
4.
5.

Establishment and evaluation of a loop-mediated isothermal amplification (LAMP) assay for the semi-quantitative detection of HIV-1 group M virus.

Odari EO, Maiyo A, Lwembe R, Gurtler L, Eberle J, Nitschko H.

J Virol Methods. 2015 Feb;212:30-8. doi: 10.1016/j.jviromet.2014.10.012. Epub 2014 Nov 6.

PMID:
25445795
6.

Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.

Kneidinger N, Giessen C, von Wulffen W, Milger K, Schramm R, Jäger G, Nitschko H, Striebinger H, Behr J, Neurohr C.

Int J Infect Dis. 2014 Nov;28:140-2. doi: 10.1016/j.ijid.2014.06.009. Epub 2014 Sep 26.

7.

A novel indirect immunofluorescence test for the detection of IgG and IgA antibodies for diagnosis of Hepatitis E Virus infections.

Osterman A, Vizoso-Pinto MG, Jung J, Jaeger G, Eberle J, Nitschko H, Baiker A.

J Virol Methods. 2013 Jul;191(1):48-54. doi: 10.1016/j.jviromet.2013.03.022. Epub 2013 Apr 1.

PMID:
23557668
8.

The polyomaviruses WUPyV and KIPyV: a retrospective quantitative analysis in patients undergoing hematopoietic stem cell transplantation.

Motamedi N, Mairhofer H, Nitschko H, Jäger G, Koszinowski UH.

Virol J. 2012 Sep 18;9:209. doi: 10.1186/1743-422X-9-209.

9.

Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences.

Aurnhammer C, Haase M, Muether N, Hausl M, Rauschhuber C, Huber I, Nitschko H, Busch U, Sing A, Ehrhardt A, Baiker A.

Hum Gene Ther Methods. 2012 Feb;23(1):18-28. doi: 10.1089/hgtb.2011.034.

PMID:
22428977
10.

Systematic screening for novel, serologically reactive Hepatitis E Virus epitopes.

Osterman A, Vizoso Pinto MG, Haase R, Nitschko H, Jäger S, Sander M, Motz M, Mohn U, Baiker A.

Virol J. 2012 Jan 23;9:28. doi: 10.1186/1743-422X-9-28.

11.

Activation of innate immune defense mechanisms contributes to polyomavirus BK-associated nephropathy.

Ribeiro A, Wörnle M, Motamedi N, Anders HJ, Gröne EF, Nitschko H, Kurktschiev P, Debiec H, Kretzler M, Cohen CD, Gröne HJ, Schlöndorff D, Schmid H.

Kidney Int. 2012 Jan;81(1):100-11. doi: 10.1038/ki.2011.311. Epub 2011 Sep 14.

12.

HCMV spread and cell tropism are determined by distinct virus populations.

Scrivano L, Sinzger C, Nitschko H, Koszinowski UH, Adler B.

PLoS Pathog. 2011 Jan 13;7(1):e1001256. doi: 10.1371/journal.ppat.1001256.

13.

A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens.

Vizoso Pinto MG, Pfrepper KI, Janke T, Noelting C, Sander M, Lueking A, Haas J, Nitschko H, Jaeger G, Baiker A.

Virol J. 2010 Jul 20;7:165. doi: 10.1186/1743-422X-7-165.

14.

Early detection of Varicella-Zoster virus (VZV)-specific T-cells before seroconversion in primary varicella infection: case report.

Baiker A, Haase R, Eberle J, Vizoso Pinto MG, Pfrepper KI, Petrich A, Deml L, Campe H, Nitschko H, Jaeger G.

Virol J. 2010 Mar 6;7:54. doi: 10.1186/1743-422X-7-54.

15.

A staining control for the HCMV pp65 antigen test.

Osterman A, Haase R, Motamedi N, Nitschko H, Jaeger G, Baiker A.

J Clin Virol. 2010 Mar;47(3):280-1. doi: 10.1016/j.jcv.2009.12.017. Epub 2010 Jan 15. No abstract available.

PMID:
20080061
16.

Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.

Raziorrouh B, Jung MC, Schirren CA, Loehe F, Thiel M, Nitschko H, Diepolder H, Ulsenheimer A, Heeg M, Zachoval R, Gruener NH.

Eur J Gastroenterol Hepatol. 2008 Aug;20(8):778-83. doi: 10.1097/MEG.0b013e3282f762f8.

PMID:
18617783
17.

Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection.

Lucas M, Ulsenheimer A, Pfafferot K, Heeg MH, Gaudieri S, Grüner N, Rauch A, Gerlach JT, Jung MC, Zachoval R, Pape GR, Schraut W, Santantonio T, Nitschko H, Obermeier M, Phillips R, Scriba TJ, Semmo N, Day C, Weber JN, Fidler S, Thimme R, Haberstroh A, Baumert TF, Klenerman P, Diepolder HM.

PLoS One. 2007 Jul 25;2(7):e649.

18.

large-scale serologic testing program to assess the immunogenicity of inactivated hepatitis a vaccine (VAQTA) in prefilled syringes following product recall in Germany.

Jäger G, Kuter B, Campe H, Lakkis H, Nitschko H, Watson M, Harzer E, Schödel F.

Hum Vaccin. 2006 Nov-Dec;2(6):233-6. Epub 2006 Nov 2.

PMID:
17204866
19.

Polyomavirus DNA and RNA detection in renal allograft biopsies: results from a European multicenter study.

Schmid H, Nitschko H, Gerth J, Kliem V, Henger A, Cohen CD, Schlöndorff D, Gröne HJ, Kretzler M.

Transplantation. 2005 Sep 15;80(5):600-4.

PMID:
16177632
20.

Undetected chronic hepatitis B virus infection of a vaccinated dialysis patient after liver transplantation.

Campe H, Hillebrand GF, Mairhofer H, Nitschko H, Jäger G.

Nephrol Dial Transplant. 2005 Jul;20(7):1492-4. Epub 2005 Apr 19. No abstract available.

PMID:
15840679
21.

Rapid enzymatic test for phenotypic HIV protease drug resistance.

Hoffmann D, Assfalg-Machleidt I, Nitschko H, von der Helm K, Koszinowski U, Machleidt W.

Biol Chem. 2003 Jul;384(7):1109-17.

PMID:
12956428
22.

Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination.

Schirren CA, Zachoval R, Gerlach JT, Ulsenheimer A, Gruener NH, Diepolder HM, Baretton G, Schraut W, Rau HG, Nitschko H, Pape GR, Jung MC.

J Hepatol. 2003 Sep;39(3):397-404.

PMID:
12927926
23.

Development and evaluation of a phenotypic assay monitoring resistance formation to protease inhibitors in HIV-1-infected patients.

Gehringer H, Von der Helm K, Seelmeir S, Weissbrich B, Eberle J, Nitschko H.

J Virol Methods. 2003 May;109(2):143-52.

PMID:
12711057
25.

Isolate KAV: a new genotype of the TT-virus family.

Heller F, Zachoval R, Koelzer A, Nitschko H, Froesner GG.

Biochem Biophys Res Commun. 2001 Dec 21;289(5):937-41.

PMID:
11741280
27.

Prevalence of GB virus C/hepatitis G virus RNA and anti-E2 glycoprotein antibodies in homosexual men with HIV coinfection.

Wächtler M, Hofmann A, Müller G, Frösner G, Nitschko H, Karwat M, Knetsch I, Emminger C, Eichenlaub D.

Infection. 2000 Sep;28(5):297-300.

PMID:
11073136
28.

Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infected patients prior to HAART and possible implications on HAART.

Gehringer H, Bogner JR, Goebel FD, Nitschko H, von der Helm K.

J Clin Virol. 2000 Aug;17(2):137-41.

PMID:
10942094
29.
30.

Molecular comparison of Mycoplasma hominis strains isolated from colonized women and women with various urogenital infections.

Busch U, Nitschko H, Pfaff F, Henrich B, Heesemann J, Abele-Horn M.

Zentralbl Bakteriol. 2000 Jan;289(8):879-88.

PMID:
10705620
31.

The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre.

Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, Muss N, Sandhofer F, Vogel W.

Gut. 1999 Apr;44(4):563-7.

32.

Methods for the differentiation of microorganisms.

Busch U, Nitschko H.

J Chromatogr B Biomed Sci Appl. 1999 Feb 5;722(1-2):263-78. Review.

PMID:
10068145
33.

Transverse myelitis associated with Mycoplasma pneumoniae infection.

Abele-Horn M, Franck W, Busch U, Nitschko H, Roos R, Heesemann J.

Clin Infect Dis. 1998 Apr;26(4):909-12.

PMID:
9564474
34.

Molecular approaches to diagnosis of pulmonary diseases due to Mycoplasma pneumoniae.

Abele-Horn M, Busch U, Nitschko H, Jacobs E, Bax R, Pfaff F, Schaffer B, Heesemann J.

J Clin Microbiol. 1998 Feb;36(2):548-51.

35.

Variability of the Hepatitis B Surface Protein in HBV-Infected Liver Transplant Recipients.

Schätzl HM, Sieger E, Jilg W, Nitschko H, Zachoval R.

J Biomed Sci. 1997 Jul-Aug;4(4):146-154.

PMID:
11725147
36.

Polymerase chain reaction for diagnosis and identification of distinct variants of Crimean-Congo hemorrhagic fever virus in the United Arab Emirates.

Schwarz TF, Nsanze H, Longson M, Nitschko H, Gilch S, Shurie H, Ameen A, Zahir AR, Acharya UG, Jager G.

Am J Trop Med Hyg. 1996 Aug;55(2):190-6.

PMID:
8780459
37.
38.

Travel-related vector-borne virus infections in Germany.

Schwarz TF, Jäger G, Gilch S, Pauli C, Eisenhut M, Nitschko H, Hegenscheid B.

Arch Virol Suppl. 1996;11:57-65.

PMID:
8800806
39.
40.

Crimean-Congo haemorrhagic fever in Oman.

Schwarz TF, Nitschko H, Jäger G, Nsanze H, Longson M, Pugh RN, Abraham AK.

Lancet. 1995 Nov 4;346(8984):1230. No abstract available.

PMID:
7475685
41.
42.

Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.

Eberle J, Bechowsky B, Rose D, Hauser U, von der Helm K, Gürtler L, Nitschko H.

AIDS Res Hum Retroviruses. 1995 Jun;11(6):671-6.

PMID:
7576926
43.

Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection.

Hoffmann RM, Diepolder HM, Zachoval R, Zwiebel FM, Jung MC, Scholz S, Nitschko H, Riethmüller G, Pape GR.

Hepatology. 1995 Mar;21(3):632-8.

PMID:
7875660
44.

Detection by PCR of human polyomaviruses BK and JC in immunocompromised individuals and partial sequencing of control regions.

Schätzl HM, Sieger E, Jäger G, Nitschko H, Bader L, Ruckdeschel G, Jäger G.

J Med Virol. 1994 Feb;42(2):138-45.

PMID:
7908940
45.

Identification, purification, and cell culture assays of retroviral proteases.

von der Helm K, Seelmeier S, Kisselev A, Nitschko H.

Methods Enzymol. 1994;241:89-104. Review. No abstract available.

PMID:
7854194
46.

The Sukhumi primate monkey model for viral lymphomogenesis: high incidence of lymphomas with presence of STLV-I and EBV-like virus.

Schätzl H, Tschikobava M, Rose D, Voevodin A, Nitschko H, Sieger E, Busch U, von der Helm K, Lapin B.

Leukemia. 1993 Aug;7 Suppl 2:S86-92.

PMID:
8395624
47.

Deletion analysis of the capsid protein of Sindbis virus: identification of the RNA binding region.

Geigenmüller-Gnirke U, Nitschko H, Schlesinger S.

J Virol. 1993 Mar;67(3):1620-6.

48.
49.

Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor.

Schätzl H, Gelderblom HR, Nitschko H, von der Helm K.

Arch Virol. 1991;120(1-2):71-81.

PMID:
1929879
50.

Inhibition of the retroviral HIV-proteinase impairs maturation to infectious human immunodeficiency virus (HIV).

Nitschko H, Schätzl H, Gelderblom HR, Oswald M, von der Helm K.

Biomed Biochim Acta. 1991;50(4-6):655-8.

PMID:
1801738

Supplemental Content

Loading ...
Support Center